PET/Computed Tomography and Patient Outcomes in Melanoma.
The performance of fludeoxyglucose F 18 (FDG)-PET/computed tomography (CT) in the initial and follow-up evaluation of patients with melanoma is well established. Groups are beginning to investigate whether the inclusion of FDG-PET/CT into a staging or surveillance algorithm results in an improvement in patient outcome and whether such an imaging program would be cost-effective.